期刊
CELL METABOLISM
卷 9, 期 1, 页码 23-34出版社
CELL PRESS
DOI: 10.1016/j.cmet.2008.11.008
关键词
-
资金
- Wellcome Trust
- EXGENESIS Integrated Project [LSHM-CT-2004-005272]
- Division of Signal Transduction Therapy at Dundee (AstraZeneca, Boeringer-Ingelheim, GlaxoSmithKline, Merck & Co. Inc, Merck KgaA, and Pfizer)
AMPK beta subunits contain a conserved domain that causes association with glycogen. Although glycogen availability is known to affect AMPK regulation in vivo, the molecular mechanism for this has not been clear. We now show that AMPK is inhibited by glycogen, particularly preparations with high branching content. We synthesized a series of branched oligosaccharides and show that those with a single alpha 1 -> 6 branch are allosteric inhibitors that also inhibit phosphorylation by upstream kinases. Removal of the outer chains of glycogen using phosphorylase, thus exposing the outer branches, renders inhibition of AMPK more potent. Inhibition by all carbohydrates tested was dependent on the glycogen-binding domain being abolished by mutation of residues required for carbohydrate binding. Our results suggest the hypothesis that AMPK, as well as monitoring immediate energy availability by sensing AMP/ATP, may also be able to sense the status of cellular energy reserves in the form of glycogen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据